Pacira BioSciences Inc (PCRX)

Industry Drug Manufacturers - Specialty & Generic

This stock can be held in an Investment ISA and an Investment Account

Sell

$23.01

Buy

$26.32

arrow-up$0.56 (+2.18%)

Prices updated at 12 Dec 2025, 22:56 EST

Prices minimum 15 mins delay

Prices in USD

Pacira Pharmaceuticals Inc is a specialty and generic drug manufacturing company. The company develops, manufactures, and commercializes pharmaceutical products for use in hospitals and ambulatory surgery centers across the United States.

NASDAQ

-1.69%

NASDAQ

Important documents: Please ensure that you have read the Pre-sale Illustrations document & Doing Business with Fidelity document (incorporating the Fidelity Client Terms) and

Our Investment Fees and Charges.

Sector

Healthcare

Industry

Drug Manufacturers - Specialty & Generic

Chairman

Ms. Laura A. Brege

CEO

Mr. Frank D. Lee

Most recent earnings

31 Dec 2024

Fiscal year end

31 Dec 2024

Employees

790

Head office

5401 West Kennedy Boulevard

Tampa

United States

33609

+1 813 553-6680

Susan.Mesco@pacira.com

Company website

Key personnel

Owner name chevron-l-regular chevron-r-regular	Salary
Ms. Laura A. Brege Chairman of the Board	0.09m
Mr. Brendan P. Teehan Chief Commercial Officer	-
Mr. Daryl Gaugler Executive Vice President, Commercial Operations	0.51m
Ms. Krys Corbett Chief Business Officer	-
Dr. Mark A. Kronenfeld, M.D. Independent Director	0.09m
Ms. Kristen Marie Williams Chief Administrative Officer and Secretary	0.52m
Mr. Michael J. Yang Independent Director	0.07m
Dr. Mark I. Froimson, M.D. Independent Director	0.07m
Mr. Abraham N. Ceesay, M.B.A. Independent Director	0.06m
Governor Christopher J. Christie Independent Director	0.05m
Mr. Shawn M. Cross Chief Financial Officer	0.10m
Mr. Frank D. Lee Director and Chief Executive Officer	0.90m
Mr. Jonathan Slonin Chief Medical Officer	0.54m
Ms. Alethia Young Independent Director	0.07m
Dr. Marcelo Bigal, M.D.,PhD Independent Director	0.07m

Top 5 shareholders

Owner name chevron-l-regular chevron-r-regular	No. of shares
BlackRock Inc	7,336,198
Vanguard Group Inc	5,405,964
BlackRock Fund Advisors	4,889,673
Doma Perpetual Capital Management LLC	2,701,324
iShares Core S&P Small-Cap ETF	2,693,379

Director dealings

Date chevron-l-regular chevron-r-regular	Action
31 Dec 2024	-
13 Dec 2024	-
04 Nov 2024	-
01 Nov 2024	-
13 Sep 2024	-
16 Aug 2024	-
16 Aug 2024	-
14 Aug 2024	-
12 Aug 2024	-
12 Aug 2024	-
12 Aug 2024	-
02 Aug 2024	-
01 Aug 2024	-
01 Jul 2024	-
28 Jun 2024	-
02 Jul 2024	-
28 Jun 2024	-
12 Jun 2024	-
12 Jun 2024	-
13 Jun 2024	-

Please note that past performance is not a reliable indicator of future returns.

Important Information

Investment values, and income from investments, can go down as well as up, so you may get back less than you invest. This is not a personal recommendation for a specific investment. If you're not sure which investments are suitable for you, consult Fidelity's advisers or another authorised financial adviser. The information contained herein: is proprietary to Morningstar and/or its content providers; may not be copied or distributed; and is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.